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Introduction: We previously reported that some forms of bovine lactoferrin (bLf) are 
effective in substantially delaying C. difficile growth and preventing production of toxins in a 
human in vitro gut model of C. difficile infection (CDI). The aim of the present study was to 
develop lactoferrin-loaded alginate microbeads coated with high molecular weight chitosan 
for enhanced protein stability, and to subsequently evaluate their anti-C. difficile defence 
properties in vitro. 
 
Methods: Different forms of bLf (iron-depleted; apo-bLf, iron-saturated; holo-bLf, and 
manganese-saturated; Mn-bLF) and BSA-FITC were encapsulated in calcium-alginate and 
chitosan-coated alginate particles. Microgel particles were fabricated using the 
emulsification/internal gelation method. Protein encapsulation efficiency was confirmed by 
fluorescence microscopy imaging of BSA-FITC-loaded hydrogel particles. In vitro release 
studies conducted in pH-simulated gastrointestinal conditions were employed to investigate 
encapsulation efficiency and release rate of encapsulated protein. The various encapsulated 
bLf forms were evaluated for their influence on intestinal epithelial barrier function and cell 
viability alone, and in combination with purified whole C. difficile toxins A and B or bacterial 
supernatant samples of the epidemic 027 C. difficile strain. Enterocyte viability and 
epithelial permeability were assessed using trypan blue exclusion, MTT cytotoxicity assay 
and changes in trans-epithelial electrical resistance (TEER) in Caco-2 cells, respectively. 
 
Results: Alginate microparticles are suitable for encapsulation and pH-triggered release of 
metal-bound bLF proteins (Figure 1). The application of bLf (5 mg/mL) delivered from 
alginate microparticles to human intestinal epithelial cells (hIECs) significantly reduced the 
cytotoxic effect of toxin A and bacterial supernatant samples on Caco-2 cells, as illustrated 
by increased TEER values and enhanced Caco-2 cell viability. Pre-treatment of Vero cell 
monolayers with all forms of encapsulated bLf followed by exposure to toxin B or bacterial 
supernatant induced a fall in mitochondrial enzyme activity. 
 
Conclusions: Our results are the first to suggest that alginate-bLf microparticles show 
protective effects against C. difficile toxin-mediated mucosal damage and impairment of 
barrier function in hIECs. The future potential of lactoferrin-loaded alginate microparticles in 
the treatment and prevention of CDI deserves further investigation in preclinical studies. 
 
 
 
